Sentences with phrase «ibrutinib with»
The new data builds off several preclinical studies supporting the use of ibrutinib with CAR therapy.
https://www.sciencedaily.com/ Not exact matches
In March 2016, Penn researchers published a study in Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in mice.
«This single - institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.
«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»
Longer follow - up will reveal the durability of these results, the authors said, and may support the evaluation of a first - line approach with ibrutinib and CAR therapy in an effort to remove the need for chronic therapy.
The study's objective is to determine if the addition of ibrutinib to standard chemotherapy can increase the cure rate of patients with ABC DLBCL.
An analysis based on disease subtype showed that ibrutinib produced complete or partial responses in 37 percent (14 of 38) of patients with ABC DLBCL but only 5 percent (1 of 20) of patients with GCB DLBCL.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B - cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.
FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 therapy.